Overall, these data suggest that increased BRD4 activity results in enhanced malignancy only in IDHmut glioma, particularly astrocytomas, whereas increased BRD3 activity results in enhanced survival only in IDHwt glioma. The gene discussed is BRD4; the disease is central nervous system cancer.